These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18292222)

  • 1. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.
    Li S; Takeuchi F; Wang JA; Fan Q; Komurasaki T; Billings EM; Pacheco-Rodriguez G; Moss J; Darling TN
    Proc Natl Acad Sci U S A; 2008 Mar; 105(9):3539-44. PubMed ID: 18292222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?
    Chan JY; Wang KH; Fang CL; Chen WY
    PLoS One; 2014; 9(2):e89467. PubMed ID: 24558502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis.
    Li S; Thangapazham RL; Wang JA; Rajesh S; Kao TC; Sperling L; Moss J; Darling TN
    Nat Commun; 2011; 2():235. PubMed ID: 21407201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
    Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
    J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development.
    Li S; Takeuchi F; Wang JA; Fuller C; Pacheco-Rodriguez G; Moss J; Darling TN
    J Exp Med; 2005 Sep; 202(5):617-24. PubMed ID: 16129702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex.
    Tyburczy ME; Wang JA; Li S; Thangapazham R; Chekaluk Y; Moss J; Kwiatkowski DJ; Darling TN
    Hum Mol Genet; 2014 Apr; 23(8):2023-9. PubMed ID: 24271014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
    Kwiatkowski DJ
    Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that TSC2 acts as a transcription factor and binds to and represses the promoter of Epiregulin.
    Pradhan SA; Rather MI; Tiwari A; Bhat VK; Kumar A
    Nucleic Acids Res; 2014 Jun; 42(10):6243-55. PubMed ID: 24748662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.
    Maruyama H; Ohbayashi C; Hino O; Tsutsumi M; Konishi Y
    Pathol Int; 2001 Aug; 51(8):585-94. PubMed ID: 11564212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missense mutations to the TSC1 gene cause tuberous sclerosis complex.
    Nellist M; van den Heuvel D; Schluep D; Exalto C; Goedbloed M; Maat-Kievit A; van Essen T; van Spaendonck-Zwarts K; Jansen F; Helderman P; Bartalini G; Vierimaa O; Penttinen M; van den Ende J; van den Ouweland A; Halley D
    Eur J Hum Genet; 2009 Mar; 17(3):319-28. PubMed ID: 18830229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catenin delta-1 (CTNND1) phosphorylation controls the mesenchymal to epithelial transition in astrocytic tumors.
    Yang J; Bassuk AG; Merl-Pham J; Hsu CW; Colgan DF; Li X; Au KS; Zhang L; Smemo S; Justus S; Nagahama Y; Grossbach AJ; Howard MA; Kawasaki H; Feldstein NA; Dobyns WB; Northrup H; Hauck SM; Ueffing M; Mahajan VB; Tsang SH
    Hum Mol Genet; 2016 Oct; 25(19):4201-4210. PubMed ID: 27516388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
    Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
    J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways-Case Report and Literature Review.
    Jurca CM; Kozma K; Petchesi CD; Zaha DC; Magyar I; Munteanu M; Faur L; Jurca A; Bembea D; Severin E; Jurca AD
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions.
    Niida Y; Stemmer-Rachamimov AO; Logrip M; Tapon D; Perez R; Kwiatkowski DJ; Sims K; MacCollin M; Louis DN; Ramesh V
    Am J Hum Genet; 2001 Sep; 69(3):493-503. PubMed ID: 11468687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
    Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of Tsc2 in Mesoderm-Derived Cells Causes Polycystic Kidney Lesions and Impairs Lung Alveolarization.
    Ren S; Luo Y; Chen H; Warburton D; Lam HC; Wang LL; Chen P; Henske EP; Shi W
    Am J Pathol; 2016 Dec; 186(12):3261-3272. PubMed ID: 27768862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex.
    Hino O; Kobayashi T
    Cancer Sci; 2017 Jan; 108(1):5-11. PubMed ID: 27862655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.